ADXN
Addex Therapeutics Ltd
stock NASDAQ ADR

addex therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. the company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including g-protein coupled receptors (gpcrs), receptor tyrosine kinases (rtks) and cytokine receptors, such as the tnf receptor superfamily. many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery. the company's two lead products are: dipraglurant (adx48621), an mglur5 negative allosteric modulator, or nam, which reduced parkinson's disease levodopa-induced dyskinesia (pd-lid) in a phase ii